Media Summary: Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for ... Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of Dr Hamid speaks with ecancertv at ESMO 2016 about the outcomes of a phase I study into the responses to combined PD-1 and ...
Exploring Medi0680 Durvalumab Versus Nivolumab - Detailed Analysis & Overview
Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for ... Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of Dr Hamid speaks with ecancertv at ESMO 2016 about the outcomes of a phase I study into the responses to combined PD-1 and ... Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the results of the Phase III NIAGARA study ... Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, highlights data coming from the DUTRENEO trial. For the past 15 years, immune checkpoint inhibitors have had a major effect on the treatment of patients with advanced melanoma ...
Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, gives an overview of the Phase III NIAGARA trial ... Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer ... Experienced Mesothelioma.net writer Terri Oppenheimer talks about Dual Immunotherapy for Mesothelioma – Rosalyn Juergens, MD, PhD of McMaster University, Juravinski Cancer Centre, Canada talks about the Canadian Clinical Trials ... David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which
